Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review

Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rationa...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Gardini, Andrea Casadei, Santini, Daniele, Aprile, Giuseppe, Silvestris, Nicola, Felli, Emanuele, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Marisi, Giorgia, Valgiusti, Martina, Passardi, Alessandro, Puzzoni, Marco, Silletta, Marianna, Brunetti, Oronzo, Cardellino, Giovanni Gerardo, Frassineti, Giovanni Luca, Scartozzi, Mario
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630448/
https://ncbi.nlm.nih.gov/pubmed/29029548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19449
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы